| ||||||||||||||
|
|
|||||||||||||

*Department of Anesthesiology,
Depertment of Anatomy, Nippon Medical School, 1-1-5, Sendagi, Bunkyoku, Tokyo, Japan
Address correspondence and reprint requests to Hiroyasu Kawahara, MD, Department of Anesthesiology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. Address e-mail to kawahara_hiroyasu/anesth{at}nms.ac.jp
Chronic constriction injury (CCI) of the sciatic nerve in rats induces persistent mechanical hyperalgesia and allodynia. CCI is widely known as a model of neuropathic pain, and many studies using this model have been reported. Recently, c-fos has been used as a neural marker of pain, and various studies have assessed the relationship between hyperalgesia and c-fos expression in the lumbar spinal cord. In this study, we examined the role of a prostaglandin E2 receptor subtype EP1 receptor antagonist (ONO-8711) in a rat CCI model. EP1 receptor antagonist (EP1-ra) oral administration from day 8 to day 14 significantly reduced hyperalgesia and allodynia in the three pain tests on day 15. EP1-ra treatment from day 8 to 14 also reduced c-fos-positive cells in laminae I-II, III-IV, and V-X compared with saline treatment. A single dose of EP1-ra treatment on day 8 significantly reduced hyperalgesia and allodynia at 1 h and 2 h after administration, but the efficacy was not observed at 24 h. We conclude that EP1-ra treatment may be useful for hyperalgesia and allodynia and that EP1 receptor mechanisms are involved in the maintenance of c-fos gene expression induced by nerve injury.
IMPLICATIONS: We examined whether a prostaglandin E2 receptor subtype EP1 receptor antagonist abrogates neuropathic pain induced by chronic constriction injury model in rats. The EP1 receptor antagonist significantly reduced hyperalgasia, allodynia, and c-fos positive cells. These findings suggested that EP1 receptor antagonists may have a role in treatment of neuropathic pain.
This article has been cited by other articles:
![]() |
C.-R. Lin, F. Amaya, L. Barrett, H. Wang, J. Takada, T. A. Samad, and C. J. Woolf Prostaglandin E2 Receptor EP4 Contributes to Inflammatory Pain Hypersensitivity J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1096 - 1103. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Conklin and J. C. Eisenach Intrathecal Ketorolac Enhances Antinociception from Clonidine Anesth. Analg., January 1, 2003; 96(1): 191 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Omote, H. Yamamoto, T. Kawamata, Y. Nakayama, and A. Namiki The Effects of Intrathecal Administration of an Antagonist for Prostaglandin E Receptor Subtype EP1 on Mechanical and Thermal Hyperalgesia in a Rat Model of Postoperative Pain Anesth. Analg., December 1, 2002; 95(6): 1708 - 1712. [Abstract] [Full Text] [PDF] |
||||
|